Quanterix Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 370

Employees

  • Stock Symbol
  • QTRX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $23.04
  • (As of Friday Closing)

Quanterix General Information

Description

Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.

Contact Information

Formerly Known As
Digital Genomics
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Primary Office
  • 900 Middlesex Turnpike
  • Building 1
  • Billerica, MA 01821
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Quanterix Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.04 $22.75 $10.02 - $28.77 $861M 37.8M 379K -$1.03

Quanterix Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 733,016 212,428 1,167,341 1,330,385
Revenue 115,553 104,952 105,339 79,955
EBITDA (46,257) (96,417) (52,470) (27,321)
Net Income (38,506) (96,700) (57,688) (31,530)
Total Assets 429,042 434,199 501,527 271,045
Total Debt 42,399 44,104 21,892 30,798
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Quanterix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Quanterix‘s full profile, request access.

Request a free trial

Quanterix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that
Diagnostic Equipment
Billerica, MA
370 As of 2022
00000
00000000 00000

000000

cing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000000000 000000000
Sunnyvale, CA
0000 As of 0000
000.00
0000000000

000000

at. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000000000 000000000
Forchheim, Germany
00000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Quanterix Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cepheid Formerly VC-backed Sunnyvale, CA 0000 000.00 0000000000
0000000 0000000000 Corporation Forchheim, Germany 00000 00.000 000000000 00.000
00 0000000000 Formerly VC-backed Lexington, MA 000 00000 00000000000 00000
000000000 Venture Capital-Backed New Richmond, WI 00 000.00 000000 - 000 000.00
00000000 000000000 Venture Capital-Backed Richmond, VA 00 000.00 00000000000 000.00
You’re viewing 5 of 20 competitors. Get the full list »

Quanterix Patents

Quanterix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220205992-A1 Materials and kits relating to association of reporter species and targeting entities with beads Pending 28-Dec-2020 000000000000 0
US-20220050106-A1 Methods and kits for detecting sars-coronavirus-2 antigen Pending 14-Aug-2020 000000000000
US-20210341479-A1 Quantitative antibody test Active 30-Apr-2020 000000000000 0
US-11686730-B2 Quantitative antibody test Active 30-Apr-2020 000000000000 00
EP-4135897-A2 Methods and systems related to highly sensitive, digital assays by improved delivery of capture objects Pending 15-Apr-2020 G01N33/54386
To view Quanterix’s complete patent history, request access »

Quanterix Executive Team (25)

Name Title Board Seat Contact Info
Masoud Toloue Ph.D Chief Executive Officer & Board Member
Vandana Sriram Chief Financial Officer, Finance
Erica Bell Chief People Officer
Darrin Crisitello Chief Commercial Officer & Senior Vice President
Naren Bhat Senior Vice President of Corporate Development and Strategy
You’re viewing 5 of 25 executive team members. Get the full list »

Quanterix Board Members (18)

Name Representing Role Since
00000 000000 Quanterix Board Member 000 0000
00000 0000 00.0 Self Board Member & Founder 000 0000
00000 00000 Self Board Member 000 0000
00000 00000000 ARCH Venture Partners Board Member 000 0000
000000 00000 Quanterix Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Quanterix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Quanterix Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
UmanDiagnostics 01-Aug-2019 0000000000 000.00 Diagnostic Equipment 00000 000
Aushon BioSystems 30-Jan-2018 Merger/Acquisition 000 Discovery Tools (Healthcare) 00000 000
To view Quanterix’s complete acquisitions history, request access »

Quanterix Subsidiaries (1)

Company Name Industry Location Founded
UmanDiagnostics Diagnostic Equipment Umea, Sweden 0000
To view Quanterix’s complete subsidiaries history, request access »

Quanterix ESG

Risk Overview

Risk Rating

Updated January, 10, 2023

20.25 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,708

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 884

Rank

0.00

Percentile

Laboratory Equipment and Services

Subindustry

00 of 67

Rank

00.0

Percentile

To view Quanterix’s complete esg history, request access »